University Hospital Erlangen at ESMO 2026

Oct 23–27, 2026 Madrid, Spain ~37k attendees Website

University Hospital Erlangen takes part in 6 sessions at ESMO 2026 in Madrid. Its program centres on breast cancer and neuroendocrine tumours, covering CDK4/6 inhibitors in early hormone receptor-positive disease and first-line care for HER2-positive metastatic breast cancer. It also addresses treatment sequencing in kidney cancer and neuroendocrine tumours, including radioligand therapy and systemic treatment of gastroenteropancreatic neuroendocrine neoplasms.

OrganizationESMO 2026 Attendance
Cancer centre & hospital
Teaching hospital of Friedrich-Alexander-Universität Erlangen-Nürnberg, in Erlangen, Germany.
Abstract
Sat Oct 24
09:00–09:10
Invited Discussant LBA51, LBA14 and 1842O
Proffered paper 2: Breast cancer, early and advanced stage
Breast cancer
Satellite
Sat Oct 24
18:30–20:00
Ipsen - Treatment decisions that shape the journey in RCC and NETs
with Gustave Roussy
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
18:33–18:43
Sequencing in an ever-changing landscape (RCC and NETs)
Ipsen - Treatment decisions that shape the journey in RCC and NETs · with Gustave Roussy
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Satellite
Sat Oct 24
19:23–19:58
Navigating the NET treatment journey
Ipsen - Treatment decisions that shape the journey in RCC and NETs · with Vall d'Hebron Institute of Oncology (VHIO)
Genitourinary cancersSarcoma, CNS, head & neck and rare cancers
Satellite
Sun Oct 25
13:00–13:05
Welcome and Introduction
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC
Breast cancer
Satellite
Sun Oct 25
13:05–13:20
Paradigm Shift: The First Changes in First-Line Treatment for HER2-Positive mBC in a Decade
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with Centre Eugène Marquis, University of Washington
Breast cancer
Satellite
Sun Oct 25
13:20–13:35
Supporting Evidence: The Data Driving Updates to the First-Line Standard of Care for HER2-Positive mBC
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with Centre Eugène Marquis, University of Washington
Breast cancer
Satellite
Sun Oct 25
13:35–13:50
Patient Selection: Identifying Candidates for Novel First-Line Regimens for HER2-Positive mBC
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with Centre Eugène Marquis, University of Washington
Breast cancer
Satellite
Sun Oct 25
13:50–14:05
Practical Implementation: Managing Care for Patients on First-Line Regimens for HER2- Positive mBC
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with Centre Eugène Marquis, University of Washington
Breast cancer
Satellite
Sun Oct 25
14:05–14:30
Questions, Take-Home Learnings, and Evaluation
Answers in CME - Building a Bridge From Evidence to Practice: Case Discussion of First-Line Treatment of HER2‑Positive mBC · with Centre Eugène Marquis, University of Washington
Breast cancer
Chair
Sun Oct 25
14:45–16:15
Radioligand therapy: A game-changer in the treatment sequence of advanced neuroendocrine tumors
with Mayo Clinic
Sarcoma, CNS, head & neck and rare cancers
Satellite
Mon Oct 26
13:00–13:05
Welcome and introduction
Novartis - From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer
Breast cancer
Satellite
Mon Oct 26
13:05–13:10
Where are we now? Current treatment landscape for patients with HR+/HER2− EBC
Novartis - From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer
Breast cancer
Satellite
Mon Oct 26
14:05–14:20
Clinical decision point 4: How can clinicians support patients on CDK4/6 inhibitor treatment if they are experiencing adverse events?
Novartis - From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer
Breast cancer
Satellite
Mon Oct 26
14:20–14:30
Key takeaways and live Q&A
Novartis - From Risk to Recurrence: Personalizing CDK4/6 Inhibitor Strategies in HR+/HER2− Breast Cancer
Breast cancer
Chair
Mon Oct 26
14:45–16:15
Endocrine tumours at a glance
Sarcoma, CNS, head & neck and rare cancers
Talk
Mon Oct 26
14:45–15:10
Key aspects in the systemic management of gastroenteropancreatic neuroendocrine neoplasms
Endocrine tumours at a glance
Sarcoma, CNS, head & neck and rare cancers

Explore the full ESMO 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Madrid. Leave your work email and we’ll be in touch.

Privacy

Download the full ESMO 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from University Hospital Erlangen

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction